The ultrasensitive liquid biopsy technique applied in this work is based on the sequencing of the entire tumour genome from…
ASCO
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with…
Initial data from the IGNYTE clinical trial demonstrate that the combination of the oncolytic virus RP1 and nivolumab (PD-1 immune…
The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment…
Josep Tabernero, Director of VHIO, has been awarded as a Fellow of the American Society of Clinical Oncology (FASCO). This…
